A13
Invazivní kardiologie v Českém ráji
| 17.–18. 6. 2013 | EA Zámecký hotel Hrubá Skála
????
Abstrakta
klinicky závažná jaterní encefalopatie (sta-
dium 3–4).
Pro riziko vzniku stenózy ve stentu je nutné
nemocné po TIPS pravidelně sledovat.
Z necelého tisíce nemocných, kteří
podstoupili TIPS ve FN Hradec Králové, jich
zhruba 10 % zemřelo do 30 dnů po výkonu,
3 roky po TIPS přežívá necelá polovina ne-
mocných.
Firemní sympozium STIMCARE
pondělí / 17. 6. 2013 / 16.45–17.15
The next scenario for 3
rd
generation
DES: shorter DAPT duration with
polymer-free Cre8
Ruggiero R.
In the last five to ten years endovascular tre-
atment in coronary vessels after Percutaneous
Transluminal Coronary Angioplasty (PTCA)
has been improved by new innovations and
new technologies.
CID’s Cre8TM Drug Eluting Stent (DES) tech-
nology and its excellent available angiographic
and clinical results enhances a better and pro-
longed DES efficacy in challenging patients, such
as diabetics, and a reduction of DAT duration
following DES implantation.
PCI in diabetic patients still represents an
area for improvement in current generation de-
vices. In fact, patient outcomes are poorer in
comparison to those of non-diabetic patients.
1
st
and 2
nd
generation DES have not yet provi-
ded the expected results in terms of efficacy.
Introducing Cre8 Drug Eluting stent as 3
rd
generation DES, the benefits of polymer-free
platform and the Bio Inducer Surface techno-
logy lower the risk of thrombosis, while the
Abluminal Reservoir Technology (ART), cont-
rolling the elution of the AmphilimusTM formu-
lation (Sirolimus plus Organic Acid), and allows
for targeted and effective drug release to-
ward the vessel wall.
Cre8’s clinical plan emphasizes the two main
objectives pursued by CID company: the first is
related to the search of a superior DES effica-
cy in the complex setting of diabetic patients
and the second is related to DES safety combi-
ned to short DAPT duration.
DAPT still represents an open question in ca-
se of DES implantation due to the fragile balance
between the risk of stent thrombosis and the
rate of bleeding events. According to a careful
evaluation of results of studies with various types
of patients, Cre8™ DES represents a step forward
in DES safety combined with short DAPT.
